Geneva, Switzerland (PRWEB) April 10, 2013
Selexis SA, a serial innovation company focused on drug discovery for lead identification and cell line development for scale-up and manufacturing of therapeutic protein drugs, announced today that representatives from the Company will be participating in the BIO International Convention’s One-on-One Partnering Meetings being held April 22 – 25, 2013 at McCormick Place in Chicago, IL.
Selexis has partnerships and commercial deals with leading biotechnology and pharmaceutical companies worldwide. Selexis’ SUREtechnology Platform™ offers a range of solutions for expressing genes in CHO cells and other mammalian systems and addresses issues such as over-expression of membrane proteins, secretion bottlenecks with difficult-to express proteins and development of high producing clonal cell lines for therapeutic protein programs. Selexis’ SUREtechnology Platform™ can be applied from early drug discovery to cGMP manufacturing, resulting in faster, more reliable, higher-expressing mammalian cell lines that can be applied to a wide range of areas such as diagnostics, drug discovery, therapeutics and bio-manufacturing.
Representatives will be available to discuss Selexis’ capabilities. Companies or individuals attending BIO 2013 can schedule meetings with Selexis by visiting (registration required): http://convention.bio.org/partner/
Selexis Business Forum Partnering Schedule:
For companies or individuals not participating in partnering meetings, Selexis will be exhibiting in booth number #4158 located in Hall C
Selexis Exhibit Hall Schedule and Partnering:
About Selexis SA
Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company’s SUREtechnology Platform™ is based on Selexis Genetic Elements™ — novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. Selexis has generated over 1,700 cell lines being used in a variety of programs from drug discovery to late-stage clinical trials.
For more information: